From predicting how nanoparticles behave in the body to anticipating treatment resistance, AI is opening new possibilities for designing cancer therapies around increasingly complex patient data.
Paper: Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design. Image Credit: banjongseal324SS / Shutterstock
In a recent review published in the journal npj Precision Oncology, researchers comprehensively examine how artificial intelligence">AI is being applied across precision oncology, with particular attention to AI-guided nanomedicine design and drug delivery.
AI Reshapes Oncology Drug Development
Precision oncology is changing cancer treatment by moving away from a one-size-fits-all approach. Instead, treatment decisions can be guided by the genetic, molecular, and biological features of each patient and their tumor.
Despite this progress, developing new cancer drugs remains expensive and slow, and promising laboratory findings often fail to translate into effective treatments. Drug resistance and the identification of useful therapeutic targets, particularly in cancers such as colorectal cancer, add to this challenge.
Artificial intelligence offers practical ways to address some of these limitations. Machine learning and deep learning can analyze large and complex datasets, including genomic, clinical, and imaging data, to identify patterns that may otherwise be missed.
These approaches can help researchers better understand disease mechanisms, predict interactions between drugs and their targets, and identify treatments suited to individual patients. AI may also improve nanomedicine by helping design and optimize more precise drug-delivery strategies.
AI Guides Nanomedicine Design
AI is increasingly being applied to nanomedicine to make the development of nanoparticle-based therapies more precise and less dependent on trial and error. Traditionally, researchers have had to test numerous formulations to find the right balance between stability, circulation time, cellular uptake, targeting, and toxicity. AI can help predict these properties earlier, allowing promising formulations to be identified before extensive laboratory testing. However, the review cautions that inconsistent nanoparticle characterization and poorly standardized datasets can limit model accuracy and generalizability.
Several emerging models illustrate this potential. NanoGPT uses deep learning to analyze lipid and structural features and guide nanoparticle formulation, while DeepCor combines surface chemistry and proteomic data to predict the protein corona that forms around nanoparticles in biological fluids. This is important because the protein corona can strongly influence where nanoparticles travel and how they interact with cells.
AI may also help personalize nanomedicine during treatment. By combining imaging, pharmacokinetic data, and patient responses, algorithms could guide adjustments to nanoparticle dose or formulation. Such closed-loop, real-time optimization remains an emerging approach rather than routine clinical practice.
In clinical research, these approaches may help identify patients most likely to benefit, improve trial design, and provide more objective measures of treatment response. Ultimately, combining AI with nanomedicine could make cancer drug delivery more targeted, adaptable, and responsive to individual patients.
AI-Driven Nanomedicine, Resistance Mitigation
Precision oncology is likely to change considerably as artificial intelligence becomes more closely integrated into cancer research, particularly in nanodrug delivery. Many long-standing problems in drug development, including high costs, lengthy development periods, and drug resistance, may be addressed more effectively through AI-based prediction and the analysis of complex biological data.
In nanomedicine, the contribution of AI goes beyond simply improving existing methods. It provides researchers with new ways to design nanocarriers with specific surface properties, more predictable biodistribution, and controlled drug-release profiles. Using AI to optimize these features could improve the therapeutic performance of nanoparticle-based treatments.
One of AI’s greatest strengths is its ability to integrate diverse types of information, ranging from molecular and genomic data to imaging results and clinical outcomes. This can reduce reliance on conventional trial-and-error approaches and support more informed nanocarrier design. Particularly interesting is the possibility of adaptive optimization during clinical treatment.
Rather than following a fixed treatment protocol, therapy could be adjusted according to changes in an individual patient’s condition and response. Real-time clinical data, interpreted with AI, could help refine dosing or delivery strategies throughout treatment. In principle, this would allow treatment to become more personalized while improving effectiveness and reducing unnecessary toxicity.
Beyond drug delivery, the review describes how AI could identify molecular signs of emerging resistance before treatment failure becomes clinically apparent. By integrating multi-omics, imaging, and clinical data, predictive models could also help researchers explore alternative drug combinations and adaptive dosing strategies intended to limit compensatory resistance mechanisms.
There are, however, important challenges to consider before such approaches can be widely adopted. Patient privacy, biased datasets, and a lack of transparency in algorithm-based decisions remain significant concerns. Data quality, standardization, model generalizability, and access to the computational infrastructure and expertise needed to implement AI are additional barriers to translation.
As AI systems become increasingly sophisticated, especially when used for tasks such as selecting patients for particular nanomedicine therapies, explainable AI (XAI) will become increasingly important. Clinicians need to be able to interpret and contextualize AI recommendations, while patients should understand how their data are being used and the limitations of AI-supported decisions. Regulatory systems will also need to keep pace with developments in AI-enabled nanomedicine without compromising patient safety.
Ultimately, translating computational advances into routine clinical practice will depend on close collaboration among researchers, clinicians, engineers, regulators, and data scientists, along with careful consideration of the broader ethical and societal consequences.
Future AI-Powered Cancer Therapies
Overall, this review highlights the growing importance of AI in precision oncology, particularly in developing more precise approaches to nanodrug delivery. AI can accelerate target discovery, support molecular design, and help develop nanocarriers with better targeting and therapeutic performance.
Tools such as NanoGPT show how AI can predict and optimize nanoparticle formulations, reducing reliance on lengthy trial-and-error approaches. The review also highlights broader applications spanning resistance prediction, multi-omics integration, digital twins, and clinical decision support.
As biological and clinical datasets expand, AI-guided nanocarriers could support increasingly predictive and adaptable approaches to cancer treatment.